GGrantIndex
← Leaderboards

Jack L Arbiser

Emory University

$5,737,275
Attributed
$5,737,275
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $491.7K · FY200522
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$5,737,275 · 4
VA$0 · 2

By mechanism

R01$5,440,710 · 2
K08$296,565 · 1
I01$0 · 2
U19$0 · 1

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Angiogenesis

Research focus

AngiogenesisCell LineHemangiomaGrowthInhibitor/AntagonistIn VivoAngiogenesis InhibitorsSkin DisorderCutaneousCellsSignal PathwayOxygenLeadNeoplasmsSmall MoleculeChildPreventMitogen Activated Protein KinaseSignal TransductionInsightBlood VesselsLesionMorbidity - Disease RatePathway Interactions

Grant awards (32)

Ceramide Analog Control of Cutaneous Inflammation$0
I01 · FY2022 · VA · contact PI
Palladium based nanoparticles for the treatment of advanced melanoma$0
I01 · FY2019 · VA · contact PI
Cutaneous Hemangiomas and Signal Transduction$343,200
R01 · FY2018 · AR · contact PI
Palladium based nanoparticles for the treatment of advanced melanoma$0
I01 · FY2018 · VA · contact PI
Cutaneous Hemangiomas and Signal Transduction$343,200
R01 · FY2017 · AR · contact PI
Palladium based nanoparticles for the treatment of advanced melanoma$0
I01 · FY2017 · VA · contact PI
Cutaneous Hemangiomas and Signal Transduction$343,200
R01 · FY2016 · AR · contact PI
Palladium based nanoparticles for the treatment of advanced melanoma$0
I01 · FY2016 · VA · contact PI
Cutaneous Hemangiomas and Signal Transduction$343,200
R01 · FY2015 · AR · contact PI
Cutaneous Hemangiomas and Signal Transduction$343,200
R01 · FY2014 · AR · contact PI
Cutaneous Hemangiomas and Signal Transduction$259,269
R01 · FY2012 · AR · contact PI
Cutaneous Hemangiomas and Signal Transduction$259,269
R01 · FY2011 · AR · contact PI
Cutaneous Hemangiomas and Signal Transduction$270,072
R01 · FY2010 · AR · contact PI
Cutaneous Hemangiomas and Signal Transduction$272,800
R01 · FY2009 · AR · contact PI
Skin Manifestations of Tuberous Sclerosis$218,943
R01 · FY2009 · AR · contact PI
Cutaneous Hemangiomas and Signal Transduction$272,800
R01 · FY2008 · AR · contact PI
Skin Manifestations of Tuberous Sclerosis$218,943
R01 · FY2008 · AR · contact PI
Skin Manifestations of Tuberous Sclerosis$223,411
R01 · FY2007 · AR · contact PI
Skin Manifestations of Tuberous Sclerosis$230,083
R01 · FY2006 · AR · contact PI
Cutaneous Hemangiomas and Signal Transduction$252,700
R01 · FY2005 · AR
Skin Manifestations of Tuberous Sclerosis$235,620
R01 · FY2005 · AR
Cutaneous Hemangiomas and Signal Transduction$252,700
R01 · FY2004 · AR
Cutaneous Hemangiomas and Signal Transduction$252,700
R01 · FY2003 · AR
Cutaneous Hemangiomas and Signal Transduction$252,700
R01 · FY2002 · AR
PATHOPHYSIOLOGY OF CUTANEOUS VASCULAR LESIONS$108,437
K08 · FY2002 · AR
SPHINGOLIPIDS REGULATION OF ANGIOGENESIS AND METASTASIS$0
U19 · FY2002 · CA
Cutaneous Hemangiomas and Signal Transduction$252,700
R01 · FY2001 · AR
PATHOPHYSIOLOGY OF CUTANEOUS VASCULAR LESIONS$108,437
K08 · FY2001 · AR
SPHINGOLIPIDS REGULATION OF ANGIOGENESIS AND METASTASIS$0
U19 · FY2001 · CA
SPHINGOLIPIDS REGULATION OF ANGIOGENESIS AND METASTASIS$0
U19 · FY2001 · CA
PATHOPHYSIOLOGY OF CUTANEOUS VASCULAR LESIONS$79,691
K08 · FY2000 · AR
SPHINGOLIPIDS REGULATION OF ANGIOGENESIS AND METASTASIS$0
U19 · FY2000 · CA